<unk>  (EDE), sold under the brand names Climacteron among others, is a long-acting estrogen medication which was previously used in menopausal hormone therapy for women and to suppress lactation in women. It was formulated in combination with estradiol benzoate (EB), a short-acting estrogen, and testosterone enanthate benzilic acid hydrazone (TEBH), a long-acting androgen/anabolic steroid. EDE has not been made available for medical use alone. The medication, in combination with EB and TEBH, was given by injection into muscle once or at regular intervals, for instance once every 6 weeks. Side effects of EDE include breast tenderness, breast enlargement, nausea, headache, and fluid retention. EDE is a synthetic estrogen and hence is an agonist of the estrogen receptor, the biological target of estrogens like estradiol. It is an estrogen ester and a prodrug of estradiol in the body. Because of this, it is considered to be a natural and bioidentical form of estrogen. EDE was first described by 1959. It was previously available in Canada and Germany but was discontinued by 2005. The medication is no longer available in any form.
Estradiol dienantate
Estradiol undecylate
Estradiol enantate
Estradiol furoate
Estradiol valerate
Estradiol dipropionate
Estradiol hemisuccinate
Estradiol diundecylenate